[CDXS] Codexis, Inc.

Overview

Type of security: Stock

Sector: Basic Industries

Industry: Major Chemicals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart CDXS

Refresh chart

Strongest Trends Summary For CDXS

CDXS is in the medium-term down -26% below S&P in 4 months and down -41% below S&P in 1 year. In the long-term up 709% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Fundamental Ratios
Shares Outstanding EPS-0.23 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.47% Sales Growth - Q/Q-52.1% P/E-20.87
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.08% ROE-84.46% ROI
Current Ratio2.33 Quick Ratio2.24 Long Term Debt/Equity Debt Ratio0.55
Gross Margin75.28% Operating Margin-52.08% Net Profit Margin-52.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-430 K Cash From Investing Activities-60 K Cash From Operating Activities-3.84 M Gross Profit5.34 M
Net Profit-5.56 M Operating Profit-5.53 M Total Assets41.42 M Total Current Assets27.63 M
Total Current Liabilities11.87 M Total Debt Total Liabilities19.8 M Total Revenue6.8 M
Technical Data
High 52 week22.57 Low 52 week13.35 Last close14.17 Last change0.07%
RSI15.42 Average true range0.74 Beta1.16 Volume24.04 K
Simple moving average 20 days-19.88% Simple moving average 50 days-21.48% Simple moving average 200 days-24.42%
Performance Data
Performance Week-19.31% Performance Month-24.39% Performance Quart-28.29% Performance Half-34.15%
Performance Year6.14% Performance Year-to-date-15.15% Volatility daily3.98% Volatility weekly8.89%
Volatility monthly18.22% Volatility yearly63.12% Relative Volume202.67% Average Volume386.81 K
New High New Low

News

2019-11-06 09:00:02 | Codexis CDXS Upgraded to Buy: What Does It Mean for the Stock?

2019-11-06 06:08:24 | Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT

2019-11-05 19:55:12 | Codexis CDXS Q3 Earnings and Revenues Beat Estimates

2019-11-05 16:05:00 | Codexis Reports Third Quarter 2019 Financial Results

2019-11-05 07:00:05 | Codexis to Participate in Four Investment Conferences in November

2019-10-29 07:00:05 | Codexis to Hold Third Quarter 2019 Conference Call on November 5

2019-10-27 20:13:14 | Is Codexis, Inc. CDXS A Good Stock To Buy ?

2019-10-26 09:13:00 | A Look At The Fair Value Of Codexis, Inc. NASDAQ:CDXS

2019-10-15 16:05:00 | Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field

2019-09-26 08:00:00 | Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit

2019-09-26 07:00:00 | Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-20 06:57:54 | Is Codexis, Inc.'s NASDAQ:CDXS CEO Pay Justified?

2019-08-29 07:11:00 | 3 Top Stocks Under $20

2019-08-22 23:15:03 | Codexis Inc CDXS President and CEO John J Nicols Bought $133,000 of Shares

2019-08-09 13:32:50 | Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-07 15:49:08 | Codexis Rolls Into Second Half Armed with Cash

2019-08-07 08:25:49 | CodexisCDXS Q2 2019 Earnings Call Transcript

2019-08-06 19:35:11 | Codexis CDXS Reports Q2 Loss, Lags Revenue Estimates

2019-08-06 16:06:00 | Codexis Reports Second Quarter 2019 Financial Results

2019-07-30 07:00:00 | Codexis to Hold Second Quarter 2019 Conference Call on August 6

2019-06-27 15:01:00 | 3 Top Stocks Under $20

2019-06-20 07:00:00 | Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives

2019-06-10 12:06:42 | Is Codexis a Buy?

2019-05-30 07:00:00 | Codexis to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-16 09:34:54 | Who Has Been Selling Codexis, Inc. NASDAQ:CDXS Shares?

2019-05-15 09:00:00 | Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader

2019-05-14 16:05:00 | Codexis to Participate at Three Investment Conferences in May

2019-05-09 10:07:43 | Codexis Bags Novartis as Software Customer, Stays Course in First Quarter

2019-05-07 10:57:05 | Hedge Funds Have Never Been This Bullish On Codexis, Inc. CDXS

2019-05-07 05:35:53 | Edited Transcript of CDXS earnings conference call or presentation 6-May-19 8:30pm GMT

2019-05-07 03:23:29 | CodexisCDXS Q1 2019 Earnings Call Transcript

2019-05-06 19:25:11 | Codexis CDXS Reports Q1 Loss, Tops Revenue Estimates

2019-05-06 18:19:44 | Codexis: 1Q Earnings Snapshot

2019-05-06 16:06:00 | Codexis Reports First Quarter 2019 Financial Results

2019-04-30 10:54:00 | 3 Stocks That Could Help You Send Your Kids to College

2019-04-30 07:00:00 | Codexis Signs Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle for the Manufacture of TASTEVA® M Stevia Sweetener

2019-04-29 07:00:00 | Codexis to Hold First Quarter 2019 Conference Call on May 6

2019-04-19 14:09:51 | Investors Who Bought Codexis NASDAQ:CDXS Shares Five Years Ago Are Now Up 1053%

2019-04-05 16:05:00 | Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign

2019-03-22 09:41:00 | 3 Stocks Poised for Huge Growth Over the Next Decade

2019-03-14 11:15:03 | Codexis CDXS Q4 Earnings Beat Estimates

2019-03-07 13:25:44 | Codexis, Inc. NASDAQ:CDXS Is Expected To Breakeven

2019-03-05 07:00:00 | Codexis to Participate in Two Investment Conferences in March

2019-03-02 11:48:10 | Codexis Inc CDXS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-01 07:45:00 | Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-27 21:57:23 | Edited Transcript of CDXS earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-27 10:18:33 | Codexis Hits the Mark in 2018, Expects Revenue to Climb 16% in 2019

2019-02-26 20:14:56 | Codexis Inc CDXS Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Codexis Reports 2018 Fourth Quarter and Full Year Financial Results

2019-02-25 07:00:00 | Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing